Genmab A/S
CSE:GMAB
Genmab A/S
Other Current Liabilities
Genmab A/S
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Other Current Liabilities
kr5.2B
|
CAGR 3-Years
51%
|
CAGR 5-Years
42%
|
CAGR 10-Years
23%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Other Current Liabilities
kr132.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Current Liabilities
€319.9m
|
CAGR 3-Years
111%
|
CAGR 5-Years
86%
|
CAGR 10-Years
45%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Current Liabilities
kr1.2B
|
CAGR 3-Years
200%
|
CAGR 5-Years
168%
|
CAGR 10-Years
12%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Other Current Liabilities
kr11.3m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Saniona AB
STO:SANION
|
Other Current Liabilities
kr77.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
88%
|
CAGR 10-Years
38%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Other Current Liabilities?
Other Current Liabilities
5.2B
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Other Current Liabilities amounts to 5.2B DKK.
What is Genmab A/S's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
23%
Over the last year, the Other Current Liabilities growth was 118%. The average annual Other Current Liabilities growth rates for Genmab A/S have been 51% over the past three years , 42% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet